Developer of molecular diagnostic kits compatible with standard PCR equipment. These kits simplify complex disease diagnosis by condensing RNA signatures into single PCR assays. This platform transforms standard qPCR machines into precision diagnostic tools. The technology integrates into existing hospital infrastructure, enabling clinicians to deliver insights. Founded in 2022, headquartered in London, United Kingdom. The company has raised $7.5M in funding at the seed stage. The company operates in the Genomics sector. Its business model centers on Oncology. Founded in 2022, headquartered in London, United Kingdom. The company has raised $7.5M at the Seed stage. Backed by investors including Y Combinator, Ukri, Gov, IBA, Riceberg Ventures.
Signatur Biosciences
SeedDeveloper of molecular diagnostic kits compatible with standard PCR equipment. These kits simplify complex disease diagnosis by condensing RNA signatures into single PCR assays. This platform transforms standard qPCR machines into precision diagnostic tools. The technology integrates into existing hospital infrastructure, enabling clinicians to deliver insights. Founded in 2022, headquartered in London, United…
About
Business model
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Precision Medicine > Oncology
Team background
College Wise > Imperial College London
Institutional investors
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.
Similar startups
Raising like Signatur Biosciences?
Analyze your pitch deck before your next raise.
Analyze My Deck →